<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-107876" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Pharmaceutical Formulation</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Afrin</surname>
            <given-names>Shanta</given-names>
          </name>
          <aff>Chittagong Medical College</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Vikas</given-names>
          </name>
          <aff>Wellness Psychiatry P.C</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shanta Afrin declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vikas Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>30</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-107876.s1" sec-type="Definition/Introduction">
        <title>Definition/Introduction</title>
        <p content-type="pubmed-excerpt">Pharmaceutical formulation is the multistep process where the active drug is mixed with all other components by considering the factors of particle size, polymorphism, pH, and solubility and becomes the final beneficial medicinal product. Benefits and constraints of the active pharmaceutical ingredients (APIs), valuable excipients, associated interactions, and manufacturing procedure are the four basic components for a successful pharmaceutical formulation.&#x000a0;The formulation often functions in a way that includes different dosage forms. The dosage form is the pharmaceutical drug product as marketed for use with a specific mixture of active ingredients and inactive components. It has to be a particular configuration(capsule shell, for example) and distributed into a particular dose.&#x000a0;</p>
        <p>Pharmaceutical formulation is the formation of a pharmaceutical product, including a drug's chemical properties, formulation, and details of the treatment protocol to be implemented in the clinical application.<xref ref-type="bibr" rid="article-107876.r1">[1]</xref>&#x000a0;There are currently tens of thousands of medication formulations available on the market for clinicians to prescribe and for patients to utilize.<xref ref-type="bibr" rid="article-107876.r2">[2]</xref><xref ref-type="bibr" rid="article-107876.r3">[3]</xref>&#x000a0;Each of these pharmaceutical formulations has had a significant amount of time and money put into the production to the combination of medications to understand how they work and to test their efficacy.<xref ref-type="bibr" rid="article-107876.r2">[2]</xref>&#x000a0;It is known that developed drugs interact with numerous proteins within the human body, and only a handful of these proteins are the targets of the medications developed; this leaves rooms for the future development of additional drugs to target the remaining proteins in the human body.<xref ref-type="bibr" rid="article-107876.r2">[2]</xref><xref ref-type="bibr" rid="article-107876.r3">[3]</xref></p>
      </sec>
      <sec id="article-107876.s2" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>With the significant amount of money invested annually, the list of medications aspires to grow each year.<xref ref-type="bibr" rid="article-107876.r1">[1]</xref>&#x000a0;However, the list stays stagnant annually as the amount of new molecular entities (NMEs) approved by the FDA annually does not increase by much because of the lack of certainty that is associated with drug design.<xref ref-type="bibr" rid="article-107876.r2">[2]</xref><xref ref-type="bibr" rid="article-107876.r4">[4]</xref>&#x000a0;Drug design means, in general, the target molecule with which the drug will bind or want to interact must have a complementary shape and charge.<xref ref-type="bibr" rid="article-107876.r5">[5]</xref>&#x000a0;It relies on computer modeling techniques and bioinformatics approaches. Computational methods frequently serve to improve the affinity, selectivity, stability, and efficacy/potency of the drug with its target molecule. There are multiple steps before marketing a drug, including the preclinical research on cell-based and animal models followed by the clinical trial on humans.<xref ref-type="bibr" rid="article-107876.r5">[5]</xref>&#x000a0;</p>
        <p>The development of pharmaceutical formulations is currently dependent on trial-and-error methods. Trial and error methods help predict optimal formulations. This process is time-consuming and expensive and involves a significant amount of labor to develop and monitor. There is pressure on the pharmaceutical industry to decrease the cost of healthcare and the number of new active pharmaceutical ingredients (APIs). To combat this, determining the desired formulations is necessary for the industry to determine efficient ways to develop drugs.<xref ref-type="bibr" rid="article-107876.r6">[6]</xref><xref ref-type="bibr" rid="article-107876.r7">[7]</xref></p>
        <p>API must be safe and efficacious, but the excipients, primary packaging materials, and devices need to be safe as well.<xref ref-type="bibr" rid="article-107876.r8">[8]</xref>&#x000a0;Before starting human trials, formulations must successfully pass various studies of preclinical (animal)&#x000a0;trials to ensure safety and efficacy. Besides the knowledge of different formulation parameters, it is significant to understand the toxicology, pharmacokinetics, chemical, and physical characterization. When minimum physicochemical characterization is over, then the work for developing formulation begins.<xref ref-type="bibr" rid="article-107876.r9">[9]</xref></p>
      </sec>
      <sec id="article-107876.s3" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>The clinical relevance of pharmaceutical formulations is that they have a significant impact on one&#x02019;s quality of life, disease outcomes, and adherence to the treatment protocol. Additionally, the effectiveness of a pharmaceutical treatment depends on a multitude of factors, including a medication&#x02019;s chemical properties, formulation, and mode of administration.<xref ref-type="bibr" rid="article-107876.r1">[1]</xref>&#x000a0;The drug must be stable and acceptable to the patient, and this is the primary consideration when developing a preparation. The drug form varies by route of administration, and identical drugs can produce different results depending on the route of administration.&#x000a0;</p>
        <p>Developed medications have maximized efficiency when used properly. More complex regimens show decreased patient compliance; thus, it is necessary to develop a low-complexity regimen for maximum effectiveness.<xref ref-type="bibr" rid="article-107876.r10">[10]</xref><xref ref-type="bibr" rid="article-107876.r11">[11]</xref><xref ref-type="bibr" rid="article-107876.r12">[12]</xref></p>
      </sec>
      <sec id="article-107876.s4" sec-type="Nursing, Allied Health, and Interprofessional Team Interventions">
        <title>Nursing, Allied Health, and Interprofessional Team Interventions</title>
        <p>It is important to develop a formulation with a regimen that is not complex for a patient to follow to improve patient outcomes through adherence to developed pharmaceutical formulations.<xref ref-type="bibr" rid="article-107876.r10">[10]</xref><xref ref-type="bibr" rid="article-107876.r11">[11]</xref><xref ref-type="bibr" rid="article-107876.r12">[12]</xref>&#x000a0;Collectively, each component of the patient care team is associated with their satisfaction with care. More recently, there has been a focus on a patient&#x02019;s satisfaction with their medication as a patient-reported outcome.<xref ref-type="bibr" rid="article-107876.r13">[13]</xref>&#x000a0;Developers need to determine a formulation route that is not a trial-and-error method but is more specialized to decrease labor and cost that is associated with the trial-and-error method and increase patient adherence to their regimens.<xref ref-type="bibr" rid="article-107876.r1">[1]</xref><xref ref-type="bibr" rid="article-107876.r2">[2]</xref><xref ref-type="bibr" rid="article-107876.r3">[3]</xref><xref ref-type="bibr" rid="article-107876.r4">[4]</xref>&#x000a0;</p>
        <p>Not only is patient compliance essential, but the collaboration of all healthcare professionals involved in healthcare is also crucial in ensuring the proper implementation of pharmaceutical formulations. The physician has to understand why and how the medication interacts with the human body. It is also imperative that nurses, pharmacists, and other essential team members maintain good communication and display accountability in administering medications to ensure patient safety.</p>
      </sec>
      <sec id="article-107876.s5" sec-type="Nursing, Allied Health, and Interprofessional Team Monitoring">
        <title>Nursing, Allied Health, and Interprofessional Team Monitoring</title>
        <p>All the health workers, including the nurse, allied health worker, and the interprofessional team, have a contributory role in the improvement of drug compliance. It is possible by sharing knowledge, and information, open communication, and collaborative decision-making. Good communication among all the above healthcare professionals can lead to better patient compliance and provide the perfect and optimal dosing by using the population and patient-specific pharmacokinetic parameters, thereby promoting medication safety through interprofessional collaboration in patient-centered care.<xref ref-type="bibr" rid="article-107876.r14">[14]</xref>&#x000a0;</p>
        <p>Correlation among the pharmacokinetics of the drug with the medical diagnosis, physical parameters, and laboratory findings can give the original information about the effectivity and compliance of the drug.<xref ref-type="bibr" rid="article-107876.r14">[14]</xref></p>
      </sec>
      <sec id="article-107876.s6">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=107876&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=107876">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/107876/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=107876">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-107876.s7">
        <title>References</title>
        <ref id="article-107876.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stewart</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Matza</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Havel</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Sweetana</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Gelhorn</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>Preference for pharmaceutical formulation and treatment process attributes.</article-title>
            <source>Patient Prefer Adherence</source>
            <year>2016</year>
            <volume>10</volume>
            <fpage>1385</fpage>
            <page-range>1385-99</page-range>
            <pub-id pub-id-type="pmid">27528802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107876.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seddon</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lounnas</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>McGuire</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>van den Bergh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bywater</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Oliveira</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vriend</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Drug design for ever, from hype to hope.</article-title>
            <source>J Comput Aided Mol Des</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>137</fpage>
            <page-range>137-50</page-range>
            <pub-id pub-id-type="pmid">22252446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107876.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Snell</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>How many medicines are there?</article-title>
            <source>Br Med J (Clin Res Ed)</source>
            <year>1985</year>
            <month>Mar</month>
            <day>09</day>
            <volume>290</volume>
            <issue>6470</issue>
            <fpage>773</fpage>
            <page-range>773-4</page-range>
            <pub-id pub-id-type="pmid">3918749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107876.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Munos</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Lessons from 60 years of pharmaceutical innovation.</article-title>
            <source>Nat Rev Drug Discov</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>8</volume>
            <issue>12</issue>
            <fpage>959</fpage>
            <page-range>959-68</page-range>
            <pub-id pub-id-type="pmid">19949401</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107876.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhou</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>WZ</given-names>
              </name>
            </person-group>
            <article-title>Drug Design and Discovery: Principles and Applications.</article-title>
            <source>Molecules</source>
            <year>2017</year>
            <month>Feb</month>
            <day>13</day>
            <volume>22</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">28208821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107876.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ouyang</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Deep learning for <italic>in vitro</italic> prediction of pharmaceutical formulations.</article-title>
            <source>Acta Pharm Sin B</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>177</fpage>
            <page-range>177-185</page-range>
            <pub-id pub-id-type="pmid">30766789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107876.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ouyang</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Big data analysis of global advances in pharmaceutics and drug delivery 1980-2014.</article-title>
            <source>Drug Discov Today</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>22</volume>
            <issue>8</issue>
            <fpage>1201</fpage>
            <page-range>1201-1208</page-range>
            <pub-id pub-id-type="pmid">28627386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107876.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thabet</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Klingmann</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Breitkreutz</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Drug Formulations: Standards and Novel Strategies for Drug Administration in Pediatrics.</article-title>
            <source>J Clin Pharmacol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>58 Suppl 10</volume>
            <fpage>S26</fpage>
            <page-range>S26-S35</page-range>
            <pub-id pub-id-type="pmid">30248193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107876.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Kaushik</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nagarsenker</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Nerurkar</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Preclinical formulations: insight, strategies, and practical considerations.</article-title>
            <source>AAPS PharmSciTech</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>5</issue>
            <fpage>1307</fpage>
            <page-range>1307-23</page-range>
            <pub-id pub-id-type="pmid">24920522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107876.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hixson-Wallace</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Dotson</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Blakey</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Effect of regimen complexity on patient satisfaction and compliance with warfarin therapy.</article-title>
            <source>Clin Appl Thromb Hemost</source>
            <year>2001</year>
            <month>Jan</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>33</fpage>
            <page-range>33-7</page-range>
            <pub-id pub-id-type="pmid">11190902</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107876.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morris</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Schulz</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Medication compliance: the patient's perspective.</article-title>
            <source>Clin Ther</source>
            <year>1993</year>
            <season>May-Jun</season>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>593</fpage>
            <page-range>593-606</page-range>
            <pub-id pub-id-type="pmid">8364951</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107876.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raue</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Schulberg</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Heo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Klimstra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bruce</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Patients' depression treatment preferences and initiation, adherence, and outcome: a randomized primary care study.</article-title>
            <source>Psychiatr Serv</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>60</volume>
            <issue>3</issue>
            <fpage>337</fpage>
            <page-range>337-43</page-range>
            <pub-id pub-id-type="pmid">19252046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107876.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shikiar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rentz</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Satisfaction with medication: an overview of conceptual, methodologic, and regulatory issues.</article-title>
            <source>Value Health</source>
            <year>2004</year>
            <season>Mar-Apr</season>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>204</fpage>
            <page-range>204-15</page-range>
            <pub-id pub-id-type="pmid">15164810</pub-id>
          </element-citation>
        </ref>
        <ref id="article-107876.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cropp</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Beall</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Buckner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wallis</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Barron</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Interprofessional Pharmacokinetics Simulation: Pharmacy and Nursing Students' Perceptions.</article-title>
            <source>Pharmacy (Basel)</source>
            <year>2018</year>
            <month>Jul</month>
            <day>20</day>
            <volume>6</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">30036982</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
